US 8,557,971 B2Granted

Chimeric viral envelopes

AssigneeAarhus Universitet

InventorsFinn Skou Pedersen, Shervin Bahrami, Mogens Ryttergaard Duch, Lars Østergaard, Martin Tolstrup

Life of this patent

Estimating the term…

Loading patent…

Abstract

The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells harboring said chimeric envelope polypeptides. Said chimeric polypeptide comprise an envelope polypeptide, or fragment thereof, and a polypeptide sequence of a receptor binding region, ligand or polypeptide sequence of a ligand binding region, and optionally a linker sequence. The invention include methods of targeting receptors, methods of treatment and methods for delivery of agents using said chimeric retroviral envelope polypeptides. The invention is applicable for directed targeting and controlled fusion of virus particles with other cellular membranes.

Claims16

Dependent claims

A polynucleotide encoding a chimeric viral envelope polypeptide comprising:

a first polypeptide into which a second polypeptide is inserted at an insertion point;
wherein the first polypeptide sequence, prior to the insertion of said second polypeptide, consists of the polypeptide sequence of a murine or feline leukemia virus envelope polypeptide whose amino acid sequence is at least 70% identical to SEQ ID NO:2;
wherein the second polypeptide sequence consists of a receptor-binding domain of a second, different viral envelope polypeptide, wherein said receptor-binding domain is from a virus selected from the group consisting of HIV, HTLV-1, hepatitis virus, vesicular stomatitis virus, cytomegalovirus, and influenza virus;
wherein the insertion point is in a region of the first polypeptide that aligns with amino acids 152 to 181 of SEQ ID NO:2 following a sequence alignment of SEQ ID NO:2 with said polypeptide sequence of a murine or feline leukemia virus envelope polypeptide whose amino acid sequence is at least 70% identical to SEQ ID NO:2;
and wherein the chimeric viral envelope polypeptide is capable of binding to the receptor of the second polypeptide sequence.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 12/225,268Filed 16 Mar 2007 · us provisional application
Priority: 17 Mar 2006
Published: US 2009/0324553 A131 Dec 2009
Granted: 15 Oct 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
A61P 31/12
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antivirals
C12N 15/86
For animal cells: viral vectors
C07K 2319/33
Fusion polypeptide: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Family

Application60/783,041Us provisional application · filed 17 Mar 2006
Application60/783,046Us provisional application · filed 17 Mar 2006
Application60/847,946Us provisional application · filed 29 Sep 2006
US 2009/0324553 A1Pre-grant publication · published 31 Dec 2009
US 8,557,971 B2This patent

From the US filing history. Foreign family members aren’t listed.